Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis

被引：21

作者：

Pucher, Philip H. ^{[1
]}

Rahman, Saqib A. ^{[1
]}

Walker, Robert C. ^{[1
]}

Grace, Ben L. ^{[1
]}

Bateman, Andrew ^{[2
]}

Iveson, Tim ^{[2
]}

Jackson, Andrew ^{[2
]}

Rees, Charlotte ^{[2
]}

Byrne, James P. ^{[1
]}

Kelly, Jamie J. ^{[1
]}

Noble, Fergus ^{[1
]}

Underwood, Timothy J. ^{[1
]}

机构：

[1] Univ Hosp Southampton, Dept Upper Gastrointestinal Surg, Southampton, Hants, England

[2] Univ Hosp Southampton, Dept Oncol, Southampton, Hants, England

来源：

EJSO | 2020年 / 46卷 / 12期

关键词：

Gastroesophageal; Adenocarcinoma; Neoadjuvant; Chemotherapy; Radiotherapy; ADENOCARCINOMA; CHEMORADIATION; METAANALYSIS; GUIDELINES; RESECTION; THERAPY; SURGERY; TRIAL;

D O I：

10.1016/j.ejso.2020.06.038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Esophageal cancer is increasingly common and carries a poor prognosis. The optimal treatment modality for locally advanced cancer is unknown, with current guidance recommending either neoadjuvant chemotherapy (CT) or chemoradiotherapy (CRT) followed by surgery. There is a lack of adequately powered trials comparing CT against CRT. We retrospectively compared CT versus CRT using a propensity score weighting approach. Methods: Demographic, disease, treatment and outcome data were retrieved from a local database for patients who received neoadjuvant CT or CRT followed by surgery. Inverse probability of treatment weighting (IPTW) was used to balance groups using a propensity score-weighting approach. Groups were assessed for differences in postoperative outcomes and survival. Kaplan-Meier and non-parametric tests were used to compare survival and outcome data as appropriate. Results: Data for 284 patients were retrieved. Following IPTW groups were well matched. No significant differences were seen for postoperative complications (CT 64.9% vs. CRT 63.3%, p = 0.807), including major complications (24.0% vs. 23.6%, p = 0.943) and anastomotic leak (7.8% vs. 5.6%, p = 0.526). Significantly higher rates of clinical regression and complete pathological response were seen following CRT (p = 0.002 for both). Rates of R0 resection were higher with CRT, CT 79.1% vs. CRT 93.1%, p = 0.006. There was no difference between groups for overall or disease-free survival. Conclusion: This study suggests that the significant improvements in local tumour response seen after neoadjuvant CRT compared to CT may not translate to different survival outcomes. However, it must be stressed that adequately powered prospective trials are still lacking. (C) 2020 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

引用

页码：2248 / 2256

页数：9

共 39 条

[1] Esophageal and Esophagogastric Junction Cancers, Version 1.2015 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Almhanna, Khaldoun ;

Bentrem, David J. ;

Besh, Stephen ;

Chao, Joseph ;

Das, Prajnan ;

Denlinger, Crystal ;

Fanta, Paul ;

Fuchs, Charles S. ;

Gerdes, Hans ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Jasperson, Kory ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Korn, W. Michael ;

Leong, Stephen ;

Lockhart, A. Craig ;

Mulcahy, Mary F. ;

Orringer, Mark B. ;

Posey, James A. ;

Poultsides, George A. ;

Sasson, Aaron R. ;

Scott, Walter J. ;

Strong, Vivian E. ;

Varghese, Thomas K., Jr. ;

Washington, Mary Kay ;

Willett, Christopher G. ;

Wright, Cameron D. ;

Zelman, Debra ;

McMillian, Nicole ;

Sundar, Hema .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (02) :194-227

[2] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[3] Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial [J].

Alderson, Derek ;

Cunningham, David ;

Nankivell, Matthew ;

Blazeby, Jane M. ;

Griffin, S. Michael ;

Crellin, Adrian ;

Grabsch, Heike I. ;

Langer, Rupert ;

Pritchard, Susan ;

Okines, Alicia ;

Krysztopik, Richard ;

Coxon, Fareeda ;

Thompson, Joyce ;

Falk, Stephen ;

Robb, Clare ;

Stenning, Sally ;

Langley, Ruth E. .

LANCET ONCOLOGY, 2017, 18 (09) :1249-1260

[4] Guidelines for the management of oesophageal and gastric cancer [J].

Allum, William H. ;

Blazeby, Jane M. ;

Griffin, S. Michael ;

Cunningham, David ;

Jankowski, Janusz A. ;

Wong, Rachel .

GUT, 2011, 60 (11) :1449-1472

[5] Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer [J].

Allum, William H. ;

Stenning, Sally P. ;

Bancewicz, John ;

Clark, Peter I. ;

Langley, Ruth E. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5062-5067

[6] Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies [J].

Austin, Peter C. ;

Stuart, Elizabeth A. .

STATISTICS IN MEDICINE, 2015, 34 (28) :3661-3679

[7] Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples [J].

Austin, Peter C. .

STATISTICS IN MEDICINE, 2009, 28 (25) :3083-3107

[8] Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial [J].

Burmeister, Bryan H. ;

Thomas, Janine M. ;

Burmeister, Elizabeth A. ;

Walpole, Euan T. ;

Harvey, Jennifer A. ;

Thomson, Damien B. ;

Barbour, Andrew P. ;

Gotley, David C. ;

Smithers, B. Mark .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (03) :354-360

[9] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].

Cunningham, David ;

Allum, William H. ;

Stenning, Sally P. ;

Thompson, Jeremy N. ;

Van de Velde, Cornelis J. H. ;

Nicolson, Marianne ;

Scarffe, J. Howard ;

Lofts, Fiona J. ;

Falk, Stephen J. ;

Iveson, Timothy J. ;

Smith, David B. ;

Langley, Ruth E. ;

Verma, Monica ;

Weeden, Simon ;

Chua, Yu Jo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20

[10] Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer [J].

Deng, Han-Yu ;

Wang, Wen-Ping ;

Wang, Yun-Cang ;

Hu, Wei-Peng ;

Ni, Peng-Zhi ;

Lin, Yi-Dan ;

Chen, Long-Qi .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2017, 51 (03) :421-431

← 1 2 3 4 →